Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
Background Reactivation of hepatitis B virus (HBV) infection is a well-recognized complication in patients with chronic or resolved HBV infection undergoing anticancer therapy. There is a risk of HBV reactivation after infusion of chimeric antigen receptor (CAR) T cells for patients with refractory/...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-07-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e000927.full |
| _version_ | 1797260280999182336 |
|---|---|
| author | Jian Zhou Lu Han Keshu Zhou Baijun Fang Linlin Li Quanli Gao Hu Zhou Yongping Song Qingsong Yin Xinghu Zhu Lingdi Zhao Xudong Wei Bengling Xu Jishuai Zhang |
| author_facet | Jian Zhou Lu Han Keshu Zhou Baijun Fang Linlin Li Quanli Gao Hu Zhou Yongping Song Qingsong Yin Xinghu Zhu Lingdi Zhao Xudong Wei Bengling Xu Jishuai Zhang |
| author_sort | Jian Zhou |
| collection | DOAJ |
| description | Background Reactivation of hepatitis B virus (HBV) infection is a well-recognized complication in patients with chronic or resolved HBV infection undergoing anticancer therapy. There is a risk of HBV reactivation after infusion of chimeric antigen receptor (CAR) T cells for patients with refractory/relapsed (R/R) multiple myeloma (MM).Methods We administered B cell maturation antigen (BCMA) CAR-T cell by infusion to nine patients with R/R MM with chronic or resolved HBV infection. Patient serum was analyzed to determine the expression of five components of HBV and the copy number of HBV DNA. HBV reactivation was defined if a patient re-exhibited hepatitis B surface antigen (HBsAg) or HBV DNA regrowth after CAR-T therapy.Results In one patient who was HBsAg-positive, no HBV reactivation was observed during the follow-up period of 9.8 months after administration of anti-HBV drugs before and after CAR-T therapy. Among eight patients with MM who had resolved HBV infection, two patients administered prophylactic anti-HBV drugs did not exhibit HBV reactivation. Of the six patients who did not use prophylactic antiviral drugs, five did not exhibit HBV reactivation, while one showed recurrence of HBsAg without detection of HBV DNA or damage to liver function. The best objective response rate was 100%, and the progression-free survival (PFS) at 12 months was of 88.89% (median PFS was not observed).Conclusions These findings showed that BCMA CAR-T cell therapy could be used in patients with R/R MM with chronic or resolved HBV infection and that antiviral drugs should be administered in these patients during CAR-T cell therapy. |
| first_indexed | 2024-04-24T23:22:49Z |
| format | Article |
| id | doaj.art-7dac7d3dc134435296335093e3d96f88 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-04-24T23:22:49Z |
| publishDate | 2020-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-7dac7d3dc134435296335093e3d96f882024-03-16T06:05:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-07-018210.1136/jitc-2020-000927Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virusJian Zhou0Lu Han1Keshu Zhou2Baijun Fang3Linlin Li4Quanli Gao5Hu Zhou6Yongping Song7Qingsong Yin8Xinghu Zhu9Lingdi Zhao10Xudong Wei11Bengling Xu12Jishuai Zhang13Institutes of Biomedical Sciences, Fudan University, Shanghai, People`s Republic of ChinaDepartment of Health Sciences, University of York, York, UK2The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan, China1 State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, ChinaResearch Units of Diagnosis and Treatment of lmmune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China1 Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Analytical Chemistry and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China10Henan Cancer Hospital, Zhengzhou, China4The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhenzhou, Henan Province, China2 Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China1 Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China2 Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China1 Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China3 The Shenzhen Pregene Biopharma Company, Ltd, Shenzhen, ChinaBackground Reactivation of hepatitis B virus (HBV) infection is a well-recognized complication in patients with chronic or resolved HBV infection undergoing anticancer therapy. There is a risk of HBV reactivation after infusion of chimeric antigen receptor (CAR) T cells for patients with refractory/relapsed (R/R) multiple myeloma (MM).Methods We administered B cell maturation antigen (BCMA) CAR-T cell by infusion to nine patients with R/R MM with chronic or resolved HBV infection. Patient serum was analyzed to determine the expression of five components of HBV and the copy number of HBV DNA. HBV reactivation was defined if a patient re-exhibited hepatitis B surface antigen (HBsAg) or HBV DNA regrowth after CAR-T therapy.Results In one patient who was HBsAg-positive, no HBV reactivation was observed during the follow-up period of 9.8 months after administration of anti-HBV drugs before and after CAR-T therapy. Among eight patients with MM who had resolved HBV infection, two patients administered prophylactic anti-HBV drugs did not exhibit HBV reactivation. Of the six patients who did not use prophylactic antiviral drugs, five did not exhibit HBV reactivation, while one showed recurrence of HBsAg without detection of HBV DNA or damage to liver function. The best objective response rate was 100%, and the progression-free survival (PFS) at 12 months was of 88.89% (median PFS was not observed).Conclusions These findings showed that BCMA CAR-T cell therapy could be used in patients with R/R MM with chronic or resolved HBV infection and that antiviral drugs should be administered in these patients during CAR-T cell therapy.https://jitc.bmj.com/content/8/2/e000927.full |
| spellingShingle | Jian Zhou Lu Han Keshu Zhou Baijun Fang Linlin Li Quanli Gao Hu Zhou Yongping Song Qingsong Yin Xinghu Zhu Lingdi Zhao Xudong Wei Bengling Xu Jishuai Zhang Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus Journal for ImmunoTherapy of Cancer |
| title | Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus |
| title_full | Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus |
| title_fullStr | Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus |
| title_full_unstemmed | Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus |
| title_short | Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus |
| title_sort | safety and efficacy of car t cell targeting bcma in patients with multiple myeloma coinfected with chronic hepatitis b virus |
| url | https://jitc.bmj.com/content/8/2/e000927.full |
| work_keys_str_mv | AT jianzhou safetyandefficacyofcartcelltargetingbcmainpatientswithmultiplemyelomacoinfectedwithchronichepatitisbvirus AT luhan safetyandefficacyofcartcelltargetingbcmainpatientswithmultiplemyelomacoinfectedwithchronichepatitisbvirus AT keshuzhou safetyandefficacyofcartcelltargetingbcmainpatientswithmultiplemyelomacoinfectedwithchronichepatitisbvirus AT baijunfang safetyandefficacyofcartcelltargetingbcmainpatientswithmultiplemyelomacoinfectedwithchronichepatitisbvirus AT linlinli safetyandefficacyofcartcelltargetingbcmainpatientswithmultiplemyelomacoinfectedwithchronichepatitisbvirus AT quanligao safetyandefficacyofcartcelltargetingbcmainpatientswithmultiplemyelomacoinfectedwithchronichepatitisbvirus AT huzhou safetyandefficacyofcartcelltargetingbcmainpatientswithmultiplemyelomacoinfectedwithchronichepatitisbvirus AT yongpingsong safetyandefficacyofcartcelltargetingbcmainpatientswithmultiplemyelomacoinfectedwithchronichepatitisbvirus AT qingsongyin safetyandefficacyofcartcelltargetingbcmainpatientswithmultiplemyelomacoinfectedwithchronichepatitisbvirus AT xinghuzhu safetyandefficacyofcartcelltargetingbcmainpatientswithmultiplemyelomacoinfectedwithchronichepatitisbvirus AT lingdizhao safetyandefficacyofcartcelltargetingbcmainpatientswithmultiplemyelomacoinfectedwithchronichepatitisbvirus AT xudongwei safetyandefficacyofcartcelltargetingbcmainpatientswithmultiplemyelomacoinfectedwithchronichepatitisbvirus AT benglingxu safetyandefficacyofcartcelltargetingbcmainpatientswithmultiplemyelomacoinfectedwithchronichepatitisbvirus AT jishuaizhang safetyandefficacyofcartcelltargetingbcmainpatientswithmultiplemyelomacoinfectedwithchronichepatitisbvirus |